Health services use by children identified as heterozygous hemoglobinopathy mutation carriers via newborn screening.
Carrier status
Health services utilization
Newborn screening
Sickle cell disease
Sickle cell trait
Journal
BMC pediatrics
ISSN: 1471-2431
Titre abrégé: BMC Pediatr
Pays: England
ID NLM: 100967804
Informations de publication
Date de publication:
01 07 2021
01 07 2021
Historique:
received:
02
03
2021
accepted:
26
05
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
7
8
2021
Statut:
epublish
Résumé
Newborn screening (NBS) for sickle cell disease incidentally identifies heterozygous carriers of hemoglobinopathy mutations. In Ontario, Canada, these carrier results are not routinely disclosed, presenting an opportunity to investigate the potential health implications of carrier status. We aimed to compare rates of health services use among children identified as carriers of hemoglobinopathy mutations and those who received negative NBS results. Eligible children underwent NBS in Ontario from October 2006 to March 2010 and were identified as carriers or as screen-negative controls, matched to carriers 5:1 based on neighbourhood and timing of birth. We used health care administrative data to determine frequencies of inpatient hospitalizations, emergency department (ED) visits, and physician encounters through March 2012, using multivariable negative binomial regression to compare rates of service use in the two cohorts. We analyzed data from 4987 carriers and 24,935 controls. Adjusted incidence rate ratios (95% CI) for service use in carriers versus controls among children < 1 year of age were: 1.11 (1.06-1.17) for ED visits; 0.97 (0.89-1.06) for inpatient hospitalization; and 1.02 (1.00-1.04) for physician encounters. Among children ≥1 year of age, adjusted rate ratios were: 1.03 (0.98-1.07) for ED visits; 1.14 (1.03-1.25) for inpatient hospitalization and 0.92 (0.90-0.94) for physician encounters. While we identified statistically significant differences in health services use among carriers of hemoglobinopathy mutations relative to controls, effect sizes were small and directions of association inconsistent across age groups and health service types. Our findings are consistent with the assumption that carrier status is likely benign in early childhood.
Sections du résumé
BACKGROUND
Newborn screening (NBS) for sickle cell disease incidentally identifies heterozygous carriers of hemoglobinopathy mutations. In Ontario, Canada, these carrier results are not routinely disclosed, presenting an opportunity to investigate the potential health implications of carrier status. We aimed to compare rates of health services use among children identified as carriers of hemoglobinopathy mutations and those who received negative NBS results.
METHODS
Eligible children underwent NBS in Ontario from October 2006 to March 2010 and were identified as carriers or as screen-negative controls, matched to carriers 5:1 based on neighbourhood and timing of birth. We used health care administrative data to determine frequencies of inpatient hospitalizations, emergency department (ED) visits, and physician encounters through March 2012, using multivariable negative binomial regression to compare rates of service use in the two cohorts. We analyzed data from 4987 carriers and 24,935 controls.
RESULTS
Adjusted incidence rate ratios (95% CI) for service use in carriers versus controls among children < 1 year of age were: 1.11 (1.06-1.17) for ED visits; 0.97 (0.89-1.06) for inpatient hospitalization; and 1.02 (1.00-1.04) for physician encounters. Among children ≥1 year of age, adjusted rate ratios were: 1.03 (0.98-1.07) for ED visits; 1.14 (1.03-1.25) for inpatient hospitalization and 0.92 (0.90-0.94) for physician encounters.
CONCLUSIONS
While we identified statistically significant differences in health services use among carriers of hemoglobinopathy mutations relative to controls, effect sizes were small and directions of association inconsistent across age groups and health service types. Our findings are consistent with the assumption that carrier status is likely benign in early childhood.
Identifiants
pubmed: 34210267
doi: 10.1186/s12887-021-02751-8
pii: 10.1186/s12887-021-02751-8
pmc: PMC8247172
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
296Références
JAMA. 2014 Sep 10;312(10):1033-48
pubmed: 25203083
Am J Forensic Med Pathol. 2009 Jun;30(2):204-8
pubmed: 19465821
Br J Sports Med. 2012 Apr;46(5):325-30
pubmed: 22442191
Health Technol Assess. 2009 Nov;13(57):1-82, iii
pubmed: 19948087
Nurs Inq. 2008 Jun;15(2):94-105
pubmed: 18476852
Ann Intern Med. 2018 Nov 6;169(9):619-627
pubmed: 30383109
Cochrane Database Syst Rev. 2004 Oct 18;(4):CD003859
pubmed: 15495068
Am J Public Health. 2009 Feb;99(2):210-5
pubmed: 19059852
EBioMedicine. 2016 Sep;11:21-22
pubmed: 27580691
J Genet Couns. 2014 Jun;23(3):409-20
pubmed: 24306142
Blood. 2017 Feb 9;129(6):799-801
pubmed: 27932373
Blood Adv. 2019 May 28;3(10):1574-1580
pubmed: 31101648
Can J Public Health. 2005 Sep-Oct;96(5):369-73
pubmed: 16238157
Patient Educ Couns. 2013 Mar;90(3):378-85
pubmed: 22240007
Cold Spring Harb Perspect Med. 2012 Sep 01;2(9):a011692
pubmed: 22951448
Health Serv Res. 2012 Feb;47(1 Pt 2):446-61
pubmed: 22150647
Eur J Hum Genet. 2010 Mar;18(3):303-8
pubmed: 19809482
Int J Lab Hematol. 2013 Jun;35(3):297-305
pubmed: 23590658
Public Health Genomics. 2014;17(1):16-22
pubmed: 24216604
Bull World Health Organ. 2008 Jun;86(6):480-7
pubmed: 18568278
J Genet Couns. 2008 Dec;17(6):538-49
pubmed: 18956236
Hematology Am Soc Hematol Educ Program. 2010;2010:418-22
pubmed: 21239829
CMAJ. 2006 Mar 14;174(6):787-91
pubmed: 16534085
Blood. 2017 Feb 9;129(6):723-728
pubmed: 27856464
Am J Hematol. 2010 Oct;85(10):797-9
pubmed: 20730795
J Med Ethics. 2009 Oct;35(10):626-34
pubmed: 19793944
J Clin Pathol. 2010 Jul;63(7):626-9
pubmed: 20591912
J Genet Couns. 2014 Oct;23(5):701-7
pubmed: 25009079
Am J Med. 2009 Jun;122(6):507-12
pubmed: 19393983
Pediatr Blood Cancer. 2014 Jan;61(1):34-9
pubmed: 24038856
Semin Perinatol. 2010 Apr;34(2):134-44
pubmed: 20207263